An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Iodine radioactive (Primary) ; Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 22 Mar 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 22 Mar 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 22 Mar 2023 Status changed from recruiting to active, no longer recruiting.